Search

Your search keyword '"Lupo, Audrey"' showing total 540 results
Start Over Author "Lupo, Audrey"
540 results on '"Lupo, Audrey"'

2. PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up

Author

Lailler, Claire, Didelot, Audrey, Garinet, Simon, Berthou, Hugo, Sroussi, Marine, de Reyniès, Aurélien, Dedhar, Shoukat, Martin-Lannerée, Séverine, Fabre, Elizabeth, Le Pimpec-Barthes, Françoise, Perrier, Alexandre, Poindessous, Virginie, Mansuet-Lupo, Audrey, Djouadi, Fatima, Launay, Jean-Marie, Laurent-Puig, Pierre, Blons, Hélène, and Mouillet-Richard, Sophie

Published
2024
Full Text
View/download PDF

6. Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practice

Author

Garinet, Simon, Lupo, Audrey, Denize, Thomas, Loyaux, Romain, Timsit, Sarah, Gazeau, Benoit, Fabre, Elizabeth, Maaradji, Zineb, Gibault, Laure, Giroux-Leprieur, Etienne, Duchemann, Boris, Monnet, Isabelle, Jouveshomme, Stéphane, Aldea, Mihaela, Besse, Benjamin, Le Pimpec-Barthes, Françoise, Leroy, Karen, Wislez, Marie, and Blons, Hélène

Published
2024
Full Text
View/download PDF

8. Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors

Author

Alexandre, Jérôme, Arrondeau, Jennifer, Boudou-Rouquette, Pascaline, De Percin, Sixtine, Kramkimel, Nora, Huillard, Olivier, Chapron, Jeanne, Deau-Fischer, Benedicte, Brandely-Piat, Marie-Laure, Damotte, Diane, Lupo, Audrey, Alifano, Marco, Corouge, Marion, Hollande, Clémence, Fontaine, Hélène, Mehiri, Lorianne Lair, Pichard, Anaïs Vallet, Tilleul, Patrick, Parlati, Lucia, Sakka, Mehdi, Retbi, Aurelia, Bouam, Samir, Hassani, Lamia, Meritet, Jean-François, Rufat, Pierre, Bonnefont-Rousselot, Dominique, Batista, Rui, Terris, Benoit, Bellanger, Agnès, Thabut, Dominique, Vozy, Aurore, Spano, Jean-Philippe, Coriat, Romain, Goldwasser, François, Aractingi, Selim, Sogni, Philippe, Pol, Stanislas, and Mallet, Vincent

Published
2023
Full Text
View/download PDF

9. Multicenter Evaluation of the Idylla GeneFusion in Non–Small-Cell Lung Cancer

Author

Depoilly, Thomas, Garinet, Simon, van Kempen, Léon C., Schuuring, Ed, Clavé, Sergi, Bellosillo, Beatriz, Ercolani, Cristiana, Buglioni, Simonetta, Siemanowski, Janna, Merkelbach-Bruse, Sabine, Tischler, Verena, Demes, Melanie-Christin, Paridaens, Henry, Sibille, Catherine, de Montpreville, Vincent Thomas, Rouleau, Etienne, Bartczak, Artur, Pasieka-Lis, Monika, Teo, Ryan Yee Wei, Chuah, Khoon Leong, Barbosa, Marta, Quintana, Carlos, Biscuola, Michele, Delgado-Garcia, Mercedes, Vacirca, Davide, Rappa, Alessandra, Cashmore, Matthew, Smith, Matthew, Jasionowicz, Piotr, Meeney, Adam, Desmeules, Patrice, Terris, Benoit, and Mansuet-Lupo, Audrey

Published
2022
Full Text
View/download PDF

13. Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.

Author

Slomka, Jeremy, Berthou, Hugo, Mansuet-Lupo, Audrey, Blons, Hélène, Fabre, Elizabeth, Lerner, Ivan, Rance, Bastien, Alifano, Marco, Chapron, Jeanne, Birsen, Gary, Gibault, Laure, Arrondeau, Jennifer, Leroy, Karen, and Wislez, Marie

Subjects
PROGRAMMED death-ligand 1, OVERALL survival, PROGRESSION-free survival, UNIVARIATE analysis, MULTIVARIATE analysis, LUNGS
Abstract

Objective: Recent evidence suggests that elevated levels of PD-L1 expression may be linked to early resistance to TKI and reduced survival in NSCLC with EGFR mutations. This study aimed to characterize the clinical and molecular features of EGFR-mutated lung adenocarcinomas and determine the prognostic significance associated with high PD-L1 expression. Materials and methods: We conducted a retrospective chart review of 103 consecutive patients with advanced EGFR-mutated NSCLC, who received treatment between 01/01/2016 and 30/12/2020, at our institution. Results: Among the tumors, 17% (n = 18) exhibited high PD-L1 expression (≥50% tumor proportion score), which was associated with a lower prevalence of common EGFR mutations (56% vs. 82%, p = 0.03) and a higher frequency of complex EGFR mutations (28% vs. 7%, p = 0.02). Univariate analysis did not reveal any significant differences in first-line response, progression-free survival, or overall survival between the PD-L1 ≥50% and <50% groups. However, multivariate analysis demonstrated that PD-L1 ≥50% was independently associated with shorter survival (HR = 2.57; 95%CI[1.20–5.55]; p = 0.02), along with male gender (HR = 2.77; 95%CI[1.54–4.19]; p<0.005), presence of liver metastases (HR = 5.80; 95%CI[2.86–11.75]; p<0.005) or brain metastases (HR = 1.99; 95%CI[1.13–3.52]; p = 0.02), and poor general condition at diagnosis (ECOG 3 and 4) (HR = 10.69; 95% CI[4.42–25.85]; p<0.005). Additionally, a trend towards a higher frequency of de novo resistance was observed in the PD-L1 >50% group (7% vs. 17%, p = 0.19). Conclusion: High PD-L1 expression was more commonly found in lung adenocarcinomas with uncommon and complex EGFR mutations. Furthermore, high PD-L1 expression independently predicted poor survival. These findings warrant validation through prospective studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study

Author

Boudou-Rouquette, Pascaline, Arrondeau, Jennifer, Gervais, Claire, Durand, Jean-Philippe, Fabre, Elizabeth, De Percin, Sixtine, Villeminey, Clémentine Vaquin, Piketty, Anne-Catherine, Rassy, Nathalie, Ulmann, Guillaume, Damotte, Diane, Mansuet-Lupo, Audrey, Giraud, Frédérique, Alifano, Marco, Wislez, Marie, Alexandre, Jérôme, Jouinot, Anne, and Goldwasser, François

Published
2021
Full Text
View/download PDF

21. Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study

Author

Molina, Thierry J., Bluthgen, Maria V., Chalabreysse, Lara, de Montpréville, Vincent T., de Muret, Anne, Dubois, Romain, Hofman, Véronique, Lantuejoul, Sylvie, le Naoures, Cécile, Mansuet-Lupo, Audrey, Parrens, Marie, Piton, Nicolas, Rouquette, Isabelle, Secq, Véronique, Girard, Nicolas, Marx, Alexander, and Besse, Benjamin

Published
2021
Full Text
View/download PDF

24. Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients

Author

Jouinot, Anne, Ulmann, Guillaume, Vazeille, Clara, Durand, Jean-Philippe, Boudou-Rouquette, Pascaline, Arrondeau, Jennifer, Tlemsani, Camille, Fournel, Ludovic, Alifano, Marco, Wislez, Marie, Chapron, Jeanne, Le Bris, Camille, Mansuet-Lupo, Audrey, Damotte, Diane, Neveux, Nathalie, De Bandt, Jean-Pascal, Alexandre, Jérôme, Cynober, Luc, and Goldwasser, François

Published
2020
Full Text
View/download PDF

25. Risk factors associated with myasthenia gravis in thymoma patients: The potential role of thymic germinal centers

Author

Lefeuvre, Claire MJ., Payet, Cloé A., Fayet, Odessa-Maud, Maillard, Solène, Truffault, Frédérique, Bondet, Vincent, Duffy, Darragh, de Montpreville, Vincent, Ghigna, Maria-Rosa, Fadel, Elie, Mansuet-Lupo, Audrey, Alifano, Marco, Validire, Pierre, Gossot, Dominique, Behin, Anthony, Eymard, Bruno, Berrih-Aknin, Sonia, and Le Panse, Rozen

Published
2020
Full Text
View/download PDF

31. Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors

Author

Mansuet-Lupo, Audrey, Barritault, Marc, Alifano, Marco, Janet-Vendroux, Aurélie, Zarmaev, Makmoud, Biton, Jérôme, Velut, Yoan, Le Hay, Christine, Cremer, Isabelle, Régnard, Jean-François, Fournel, Ludovic, Rance, Bastien, Wislez, Marie, Laurent-Puig, Pierre, Herbst, Ronald, Damotte, Diane, and Blons, Hélène

Published
2019
Full Text
View/download PDF

33. PrPCcontrols epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up

Author

Lailler, Claire, Didelot, Audrey, Garinet, Simon, Berthou, Hugo, Sroussi, Marine, de Reyniès, Aurélien, Dedhar, Shoukat, Martin-Lannerée, Séverine, Fabre, Elizabeth, Le Pimpec-Barthes, Françoise, Perrier, Alexandre, Poindessous, Virginie, Mansuet-Lupo, Audrey, Djouadi, Fatima, Launay, Jean-Marie, Laurent-Puig, Pierre, Blons, Hélène, and Mouillet-Richard, Sophie

Abstract

Patients with EGFR-mutated non-small cell lung cancer (NSCLC) benefit from treatment with tyrosine kinase inhibitors (TKI) targeting EGFR. Despite improvements in patient care, especially with the 3rd generation TKI osimertinib, disease relapse is observed in all patients. Among the various processes involved in TKI resistance, epithelial-to-mesenchymal transition (EMT) is far from being fully characterized. We hypothesized that the cellular prion protein PrPCcould be involved in EMT and EGFR-TKI resistance in NSCLC. Using 5 independent lung adenocarcinoma datasets, including our own cohort, we document that the expression of the PRNPgene encoding PrPCis associated with EMT. By manipulating the levels of PrPCin different EGFR-mutated NSCLC cell lines, we firmly establish that the expression of PrPCis mandatory for cells to maintain or acquire a mesenchymal phenotype. Mechanistically, we show that PrPCoperates through an ILK-RBPJ cascade, which also controls the expression of EGFR. Our data further demonstrate that PrPClevels are elevated in EGFR-mutated versus wild-type tumours or upon EGFR activation in vitro. In addition, we provide evidence that PRNPlevels increase with TKI resistance and that reducing PRNPexpression sensitizes cells to osimertinib. Finally, we found that plasma PrPClevels are increased in EGFR-mutated NSCLC patients from 2 independent cohorts and that their longitudinal evolution mirrors that of disease. Altogether, these findings define PrPCas a candidate driver of EMT-dependent resistance to EGFR-TKI in NSCLC. They further suggest that monitoring plasma PrPClevels may represent a valuable non-invasive strategy for patient follow-up and warrant considering PrPC-targeted therapies for EGFR-mutated NSCLC patients with TKI failure.

Published
2024
Full Text
View/download PDF

34. AB004. Basaloid carcinoma of the thymus: experience of the RYTHMIC network over an 8-year period

Author

Piton, Nicolas, primary, Mansuet-Lupo, Audrey, additional, Chalabreysse, Lara, additional, Dubois, Romain, additional, Hofman, Véronique, additional, Le Naoures, Cécile, additional, de Montpréville, Vincent Thomas, additional, De Muret, Anne, additional, Parrens, Marie, additional, Rouquette, Isabelle, additional, Secq, Véronique, additional, Dales, Jean-Philippe, additional, Sizaret, Damien, additional, Missy, Pascale, additional, Tran, Quân, additional, Bazéli, Édith, additional, Marx, Alexander, additional, Girard, Nicolas, additional, Besse, Benjamin, additional, and Molina, Thierry Jo, additional

Published
2023
Full Text
View/download PDF

35. Usefulness of an RNA extraction-free test for the multiplexed detection of ALK , ROS1 , and RET Gene Fusions in Real Life FFPE Specimens of Non-Small Cell Lung Cancers

Author

Damiola, Francesca, primary, Alberti, Laurent, additional, Mansuet-Lupo, Audrey, additional, Damotte, Diane, additional, Hofman, Véronique, additional, Tixier, Lucie, additional, Penault-Llorca, Frédérique, additional, Rouquette, Isabelle, additional, Vignaud, Jean Michel, additional, Cazes, Aurélie, additional, Forest, Fabien, additional, Begueret, Hugues, additional, Gibault, Laure, additional, Badoual, Cécile, additional, Cayre, Anne, additional, Taranchon-Clermont, Estelle, additional, Duc, Adeline, additional, Mc Leer, Anne, additional, and Lantuejoul, Sylvie, additional

Published
2023
Full Text
View/download PDF

37. Pericardial effusion under nivolumab: case-reports and review of the literature

Author

Saade Anastasia, Mansuet-Lupo Audrey, Arrondeau Jennifer, Thibault Constance, Mirabel Mariana, Goldwasser François, Oudard Stéphane, and Weiss Laurence

Subjects
Immune checkpoint inhibitor, Nivolumab, Immune-related adverse event, Pericardial effusion, Tamponade, Cardiotoxicity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Nivolumab, a programmed death-1 (PD-1) inhibitor, is an immune checkpoint inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer and renal cell carcinoma. Immune-related adverse events are frequent under immunotherapies. Cardiotoxic side effects, initially thought to be rare, are more often encountered paralleling the expanding use of immune checkpoint blockade. Among them, pericardial effusion and tamponade deserve attention as they may present with unusual symptomatology. Case presentation We report three cases of pericardial effusion under nivolumab for lung adenocarcinoma. Two cases of early and late-onset pericardial effusion were symptomatic with tamponade and one case occurred without any symptoms. Pericardiocentesis with pericardial biopsy was performed in symptomatic pericardial effusion followed by the administration of a corticotherapy. Pericardial biopsies showed infiltration of T-lymphocytes, mostly CD4+. Nivolumab was stopped in two cases and resumed for one patient. Pericardial effusion evolved positively in all cases with or without treatment. Conclusions We review the literature on pericardial effusion under nivolumab to further discuss the hallmarks of pericardial effusion under nivolumab and the management of nivolumab therapy in this situation. In conclusion, pericardial effusion as an immune-related adverse event under nivolumab appears less rare than initially thought and may require particular attention.

Published
2019
Full Text
View/download PDF

39. Tests immunohistochimiques PD-L1 dans les cancers du poumon non à petites cellules : recommandations par le groupe PATTERN de pathologistes thoraciques

Author

Lantuejoul, Sylvie, Adam, Julien, Girard, Nicolas, Duruisseaux, Mickael, Mansuet-Lupo, Audrey, Cazes, Aurélie, Rouquette, Isabelle, Gibault, Laure, Garcia, Stéphane, Antoine, Martine, Vignaud, Jean Michael, Galateau-Sallé, Françoise, Sagan, Christine, Badoual, Cécile, Penault-Llorca, Frédérique, and Damotte, Diane

Published
2018
Full Text
View/download PDF

42. Lung Involvement in Chronic Schistosomiasis with Bladder Squamous Cell Carcinoma

Author

Saade, Anastasia, Carton, Edith, Mansuet-Lupo, Audrey, Jouffroy, Romain, Damotte, Diane, Yera, Helene, Revel, Marie-Pierre, and Goldwasser, Francois

Subjects
Squamous cell carcinoma -- Case studies -- Diagnosis, Schistosomiasis -- Case studies -- Diagnosis, Lung -- Health aspects, Health
Abstract

A 30-year-old man from Mali, who had immigrated to France a year before, was hospitalized for acute urinary retention. The patient reported isolated hematuria over the preceding month with recent [...]

Published
2018

43. Movie S2 from CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1

Author

Kantari-Mimoun, Chahrazade, primary, Barrin, Sarah, primary, Vimeux, Lene, primary, Haghiri, Sandrine, primary, Gervais, Claire, primary, Joaquina, Sandy, primary, Mittelstaet, Joerg, primary, Mockel-Tenbrinck, Nadine, primary, Kinkhabwala, Ali, primary, Damotte, Diane, primary, Lupo, Audrey, primary, Sibony, Mathilde, primary, Alifano, Marco, primary, Dondi, Elisabetta, primary, Bercovici, Nadège, primary, Trautmann, Alain, primary, Kaiser, Andrew D., primary, and Donnadieu, Emmanuel, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Tables from Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade

Author

Daugan, Marie V., primary, Revel, Margot, primary, Thouenon, Romane, primary, Dragon-Durey, Marie-Agnès, primary, Robe-Rybkine, Tania, primary, Torset, Carine, primary, Merle, Nicolas S., primary, Noé, Rémi, primary, Verkarre, Virginie, primary, Oudard, Stephane Marie, primary, Mejean, Arnaud, primary, Validire, Pierre, primary, Cathelineau, Xavier, primary, Sanchez-Salas, Rafael, primary, Pickering, Mathew C., primary, Cremer, Isabelle, primary, Mansuet-Lupo, Audrey, primary, Alifano, Marco, primary, Sautès-Fridman, Catherine, primary, Damotte, Diane, primary, Fridman, Wolf H., primary, and Roumenina, Lubka T., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Data from Acute Influenza Infection Promotes Lung Tumor Growth by Reprogramming the Tumor Microenvironment

Author

Garmendia, Irati, primary, Varthaman, Aditi, primary, Marmier, Solenne, primary, Angrini, Mahmud, primary, Matchoua, Ingrid, primary, Darbois-Delahousse, Aurelie, primary, Josseaume, Nathalie, primary, Foy, Pierre-Emmanuel, primary, Roumenina, Lubka T., primary, Naouar, Naïra, primary, Meylan, Maxime, primary, Sibéril, Sophie, primary, Russick, Jules, primary, Joubert, Pierre-Emmanuel, primary, Leroy, Karen, primary, Damotte, Diane, primary, Mansuet-Lupo, Audrey, primary, Wislez, Marie, primary, Alifano, Marco, primary, Menger, Laurie, primary, Garcia-Verdugo, Ignacio, primary, Sallenave, Jean-Michel, primary, Lantz, Olivier, primary, Petitprez, Florent, primary, and Cremer, Isabelle, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figures from Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade

Author

Daugan, Marie V., primary, Revel, Margot, primary, Thouenon, Romane, primary, Dragon-Durey, Marie-Agnès, primary, Robe-Rybkine, Tania, primary, Torset, Carine, primary, Merle, Nicolas S., primary, Noé, Rémi, primary, Verkarre, Virginie, primary, Oudard, Stephane Marie, primary, Mejean, Arnaud, primary, Validire, Pierre, primary, Cathelineau, Xavier, primary, Sanchez-Salas, Rafael, primary, Pickering, Mathew C., primary, Cremer, Isabelle, primary, Mansuet-Lupo, Audrey, primary, Alifano, Marco, primary, Sautès-Fridman, Catherine, primary, Damotte, Diane, primary, Fridman, Wolf H., primary, and Roumenina, Lubka T., primary

Published
2023
Full Text
View/download PDF

47. Figure S1 from CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1

Author

Kantari-Mimoun, Chahrazade, primary, Barrin, Sarah, primary, Vimeux, Lene, primary, Haghiri, Sandrine, primary, Gervais, Claire, primary, Joaquina, Sandy, primary, Mittelstaet, Joerg, primary, Mockel-Tenbrinck, Nadine, primary, Kinkhabwala, Ali, primary, Damotte, Diane, primary, Lupo, Audrey, primary, Sibony, Mathilde, primary, Alifano, Marco, primary, Dondi, Elisabetta, primary, Bercovici, Nadège, primary, Trautmann, Alain, primary, Kaiser, Andrew D., primary, and Donnadieu, Emmanuel, primary

Published
2023
Full Text
View/download PDF

48. Data from CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1

Author

Kantari-Mimoun, Chahrazade, primary, Barrin, Sarah, primary, Vimeux, Lene, primary, Haghiri, Sandrine, primary, Gervais, Claire, primary, Joaquina, Sandy, primary, Mittelstaet, Joerg, primary, Mockel-Tenbrinck, Nadine, primary, Kinkhabwala, Ali, primary, Damotte, Diane, primary, Lupo, Audrey, primary, Sibony, Mathilde, primary, Alifano, Marco, primary, Dondi, Elisabetta, primary, Bercovici, Nadège, primary, Trautmann, Alain, primary, Kaiser, Andrew D., primary, and Donnadieu, Emmanuel, primary

Published
2023
Full Text
View/download PDF

49. Data from Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade

Author

Daugan, Marie V., primary, Revel, Margot, primary, Thouenon, Romane, primary, Dragon-Durey, Marie-Agnès, primary, Robe-Rybkine, Tania, primary, Torset, Carine, primary, Merle, Nicolas S., primary, Noé, Rémi, primary, Verkarre, Virginie, primary, Oudard, Stephane Marie, primary, Mejean, Arnaud, primary, Validire, Pierre, primary, Cathelineau, Xavier, primary, Sanchez-Salas, Rafael, primary, Pickering, Mathew C., primary, Cremer, Isabelle, primary, Mansuet-Lupo, Audrey, primary, Alifano, Marco, primary, Sautès-Fridman, Catherine, primary, Damotte, Diane, primary, Fridman, Wolf H., primary, and Roumenina, Lubka T., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Table 1 from CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1

Author

Kantari-Mimoun, Chahrazade, primary, Barrin, Sarah, primary, Vimeux, Lene, primary, Haghiri, Sandrine, primary, Gervais, Claire, primary, Joaquina, Sandy, primary, Mittelstaet, Joerg, primary, Mockel-Tenbrinck, Nadine, primary, Kinkhabwala, Ali, primary, Damotte, Diane, primary, Lupo, Audrey, primary, Sibony, Mathilde, primary, Alifano, Marco, primary, Dondi, Elisabetta, primary, Bercovici, Nadège, primary, Trautmann, Alain, primary, Kaiser, Andrew D., primary, and Donnadieu, Emmanuel, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results